Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Imv Inc (IMV)

Imv Inc (IMV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
IMV Receives NASDAQ Delisting Notice Business Wire - Mon May 8, 2023

IMV Inc. (the “ Company ” or “ IMV ”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX ® platform...

IMV.TO : 1.12 (-1.75%)
IMV : 0.8225 (-2.55%)
Horizon Technology Finance Announces First Quarter 2023 Financial Results PR Newswire - Tue May 2, 2023

/PRNewswire/ -- Horizon Technology Finance Corporation (NASDAQ: HRZN) ("HRZN", "Horizon" or the "Company"), a leading specialty finance company that provides...

HRZN : 10.46 (-2.06%)
IMV : 0.8225 (-2.55%)
IMV Initiates Restructuring Proceedings Under the CCAA to Complete the Review of its Strategic Alternatives Business Wire - Mon May 1, 2023

IMV Inc. (the “ Company ” or “ IMV ”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical Company developing a portfolio of immune-educating therapies based on its novel DPX ® platform...

IMV.TO : 1.12 (-1.75%)
IMV : 0.8225 (-2.55%)
IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency Business Wire - Fri Mar 31, 2023

IMV Inc. (“ IMV ” or the “ Company ”) (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to treat solid and...

IMV.TO : 1.12 (-1.75%)
IMV : 0.8225 (-2.55%)
IMV Inc. Announces Changes to Its Board of Directors Business Wire - Mon Mar 27, 2023

IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today announced...

IMV.TO : 1.12 (-1.75%)
IMV : 0.8225 (-2.55%)
IMV Inc. Announces Strategic Update as well as Fourth Quarter and Full Year 2022 Financial and Operational Results Business Wire - Thu Mar 16, 2023

IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic...

IMV.TO : 1.12 (-1.75%)
IMV : 0.8225 (-2.55%)
IMV Inc. to Announce Fourth Quarter and Fiscal Year 2022 Results and Host a Conference Call and Webcast on March 16, 2023 Business Wire - Thu Mar 9, 2023

IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today announced...

IMV.TO : 1.12 (-1.75%)
IMV : 0.8225 (-2.55%)
IMV Inc. Presents Positive Initial Results From The MVP-S Phase 2B VITALIZE Trial Business Wire - Mon Feb 13, 2023

IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to...

IMV.TO : 1.12 (-1.75%)
IMV : 0.8225 (-2.55%)
IMV Inc. Announces Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic, MVP-S Business Wire - Sun Jan 8, 2023

IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to...

IMV.TO : 1.12 (-1.75%)
IMV : 0.8225 (-2.55%)
IMV Announces Closing of US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Business Wire - Tue Dec 20, 2022

IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company advancing a portfolio of therapies based on the Company’s immune-educating platform, DPX...

IMV.TO : 1.12 (-1.75%)
IMV : 0.8225 (-2.55%)

Barchart Exclusives

3 Blue-Chip Dividend Stocks to Buy in Q4 Barchart - Sat Oct 12, 10:45AM CDT
As we move further into the final quarter of this year, analysts believe these three blue-chip dividend stocks could be ideal long-term investment candidates for your portfolio. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot